Procter & Gamble to Acquire Thorne to Boost Health and Wellness Portfolio
Key Facts
In a move reflecting the drive by major consumer goods companies to capture a larger share of the expanding wellness market, Procter & Gamble has announced its intention to acquire the Thorne supplements brand. According to the company's CEO, this strategic acquisition is designed to expand P&G's health business. The deal aims to accelerate growth within the personal healthcare segment by capitalizing on the premium health and wellness market.
The acquisition follows recent earnings reports as P&G seeks to bolster its margins through high-quality healthcare products. Per market data, PG stock closed at $144.98 (close August 03, 2026), having traded between a day high of $147.15 and a day low of $144.26 during that session.
Investors are now watching how this acquisition will drive long-term growth while PG shares maintain their current levels. Looking at the broader economic context, the markets recently processed the Fed's decision to hold interest rates at 3.75% on July 29, 2026, providing a stable financing environment for M&A activity in the consumer sector.
Latest Updates · 4
- Notable·
Update: Reports indicate the acquisition is valued at approximately $3.8 billion in cash, payable to the global investment firm L Catterton. This definitive agreement provides clarity on P&G's capital commitment toward its expansion into the supplements sector.
- Notable·
Update: Subsequent reports have valued Procter & Gamble's acquisition of Thorne at $3.8 billion. This valuation represents a significant investment, signaling the company's confidence in the long-term returns of the premium supplement sector.
- Notable·
Update: Thorne announced on August 4, 2026, that it has entered into a definitive agreement to be acquired by The Procter & Gamble Company. Thorne, headquartered in Summerville, South Carolina, marks this signing as a critical step toward the formal completion of the deal.
- Notable·
Update: P&G CEO Shailesh Jejurikar confirmed in a CNBC interview that the acquisition of Thorne is valued at $3.8 billion. This financial disclosure highlights the scale of the investment the group is making to solidify its position in the supplements market.